Stryker Corp

Discover why institutional investors and analysts are bullish on Stryker Corp, the $135 billion medical‑device leader, after its Q4 2025 earnings beat and upgraded price targets.

Stryker Corporation has launched its next-generation InThrill Thrombectomy System, a medical device designed to improve treatment of small vessel and arteriovenous thrombosis.

Stryker Corp has secured FDA clearance for its OptaBlate BVN System, bolstering its market position and maintaining its strong valuation in the medical technology industry.